PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis.
about
A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma.Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab.Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.Epidermal growth factor receptor vIII expression in U87 glioblastoma cells alters their proteasome composition, function, and response to irradiation.Dexamethasone-induced oxidative stress enhances myeloma cell radiosensitization while sparing normal bone marrow hematopoiesisBortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity.Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma.Beyond Palliation: Therapeutic Applications of 153Samarium-EDTMP.Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myelomaInterleukin-6 counteracts therapy-induced cellular oxidative stress in multiple myeloma by up-regulating manganese superoxide dismutaseRadioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene.The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killingMitochondrial-Targeted Decyl-Triphenylphosphonium Enhances 2-Deoxy-D-Glucose Mediated Oxidative Stress and Clonogenic Killing of Multiple Myeloma CellsBortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.Clinical development of novel proteasome inhibitors for cancer treatment.Concurrent whole brain radiotherapy and bortezomib for brain metastasis.Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo.Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma.Cardiac glycoside induces cell death via FasL by activating calcineurin and NF-AT, but apoptosis initially proceeds through activation of caspases.Oleandrin-mediated expression of Fas potentiates apoptosis in tumor cells.Effects of celecoxib on cell apoptosis and Fas, FasL and Bcl-2 expression in a BGC-823 human gastric cancer cell line.Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity.Bortezomib sensitizes esophageal squamous cancer cells to radiotherapy by suppressing the expression of HIF-1α and apoptosis proteins.
P2860
Q33396522-E664CE9D-DB26-4397-9551-911A3BCB3BF1Q33414603-24E803B0-733D-4E79-BAA7-4C26253AF429Q33441292-BBAF4F7B-B028-4458-875F-2364AB84BDF5Q33880422-E7BAF0C0-D0CB-426A-ADD4-DE7B2FF98486Q34411693-1D06D7FF-904C-451D-9467-AEE4CA94CA14Q34576976-45533575-008F-4E74-B342-0459C1C2D060Q35024457-4EB651A6-F828-4DDC-9710-5F8AE9EB3ABFQ35057029-7ECA68A2-A956-4860-B3A0-B94AC69CD299Q35848298-286C1099-67E0-4B08-B0FA-42B1E47E8B4EQ36002035-4A7BE7A6-0845-48EC-8B1A-604E4CDD2B48Q36007610-C95BF9D8-C702-401F-9DB7-DB386E3CA400Q36126003-B90D3715-25B7-496C-938A-93B8D5E6C031Q36208283-EE617E33-531F-4036-88C5-071A0303E36EQ36407085-9DE27E0E-310F-4049-AB59-C1AD766B6CA8Q36589122-99DAEF9A-90CB-4D18-AD13-92640BCE5155Q37136598-AEAB3C27-5A63-4B40-BC4C-731F87ABF425Q37152456-C77C31B7-6191-4415-86C3-BB15D6370376Q37381298-3DA7A7CB-4B72-4FBD-93A8-41C8495301FFQ37940343-F976CF9B-E746-424A-9E7A-694B824CD9D5Q40186826-9AD8806D-5D7F-4129-9562-E0AB03F474E7Q40266680-ABD55A20-0A79-4F3F-BB23-817AF487CEEBQ41672403-DFDE0226-BB94-47C3-A9E5-BDD36C17A469Q52538370-1D8C17F4-2113-4E99-A5B4-D3342FCFDB52Q52874910-9EB9A6EE-316A-4658-B44C-08D8A16B3C41
P2860
PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
PS-341-mediated selective targ ...... g radiation-induced apoptosis.
@en
type
label
PS-341-mediated selective targ ...... g radiation-induced apoptosis.
@en
prefLabel
PS-341-mediated selective targ ...... g radiation-induced apoptosis.
@en
P2093
P1476
PS-341-mediated selective targ ...... g radiation-induced apoptosis.
@en
P2093
Apollina Goel
Philip R Greipp
Ruben A Mesa
Thomas E Witzig
P304
P356
10.1016/J.EXPHEM.2005.04.005
P577
2005-07-01T00:00:00Z